312 results
424B5
GOVX
Geovax Labs Inc
21 May 24
Prospectus supplement for primary offering
12:32pm
trials for a next-generation Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Additional research and development … such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including
8-K
EX-99.1
GOVX
Geovax Labs Inc
15 May 24
GeoVax Reports First Quarter 2024 Financial Results
4:03pm
, as compared to $4,037,916, or $2.30 per share, for the three months ended March 31, 2023.
R&D Expenses: Research and development expenses were $4,425,728 … in thousands, except common share information)
Three Months Ended
March 31,
Operating expenses:
Research and development
General and administrative
Loss
424B3
GOVX
Geovax Labs Inc
14 May 24
Prospectus supplement
5:09pm
for advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (monkeypox … substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates and will require additional funding
424B3
GOVX
Geovax Labs Inc
14 May 24
Prospectus supplement
5:09pm
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended March 31,
Operating expenses:
Research and development
General and administrative … preclinical research and development programs include preventive vaccines against Mpox (monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola
424B3
2u35pk4usc7oy vuk0yo
14 May 24
Prospectus supplement
5:08pm
424B3
qwah2889i jo4usm8wn
14 May 24
Prospectus supplement
5:07pm
8-K
EX-99.1
wu5ej00
1 Mar 24
GeoVax Reports 2023 Year-End Financial Results
4:09pm
POS AM
bmukk 9co6
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
POS AM
sryeieim9 zsp9os1
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
POS AM
95eathau1bgo u1tu
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
POS AM
kvt38khk
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
424B3
uoysbho70
12 Jan 24
Prospectus supplement
4:00pm